NCT00948090 2014-07-31
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2 Completed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Texas Oncology Cancer Center
Targazyme, Inc.